Genomes and Genes
Quantification and monitoring inflammation in IBD with Molecular Ultrasound
Principal Investigator: JUERGEN KARL WILLMANN
Abstract: DESCRIPTION (provided by applicant): Inflammatory bowel disease (IBD) which includes Crohn's disease and ulcerative colitis affects about 1.4 million patients in the United States, including many children and young adults. It is characterized by extensive inflammatory changes in the bowel wall with overexpression of molecular inflammation markers such as P- selectin on vascular endothelial cells in the bowel wall. Due to the chronicity of IBD with multipl relapses and long treatment phases including drugs such as immunosuppressants and -modulators that are associated with major side-effects, regular and accurate monitoring of the disease's activity is of paramount importance. Since multiple follow-up exams are needed, often over many years, monitoring should be noninvasive and, above all, patient-friendly. Currently, a simple technique that meets all these requirements is not available. Ultrasound (US) is a non-invasive imaging approach that already meets many of those requirements because 1) it is widely available at relatively low cost, and 2) it does not expose patients to ionizing irradiation (which is very important for repetitive examinations in particular in children and young adults). However, current US technology lacks the sensitivity and specificity to accurately quantify inflammation in the bowel wall. Furthermore, imaging the bowel with US can be technically challenging (e.g., spatial orientation within the large volume of the bowel, possible artifacts fro intraluminal gas, motion, etc). In this grant proposal we combine the advantages of US with those of molecular imaging and develop a molecular US imaging strategy using novel contrast microbubbles that allow inflammation imaging at the molecular level. We have designed a clinical grade microbubble that targets the inflammation marker P-selectin (P-MB) with the goal to transition molecular US for monitoring inflammation into clinical trials. In specific aim 1, we will test molecular US using novel clinical grade P-MB for imaging and quantification of inflammation at the molecular level in a murine IBD model. In specific aim 2, we will compare its potential for monitoring inflammation in IBD to 18FDG-PET-CT and DCE-MRI, using ex vivo assays as the gold standard. In specific aim 3, we will translate our imaging approach from small to large animals in a porcine IBD model as a further step towards clinical translation. Critical data on the feasibility of an optimized molecular US imaging approach in porcine models of IBD (including terminal ileitis and colitis) will be obtained including the opportunity to correate in vivo imaging signals with ex vivo P- selectin expression levels and assessing optimal dosing of novel P-MB in pigs before eventual translation of our novel imaging approach into first-in-human clinical trials. We will also develop and test a novel real-time fused MRI/molecular US imaging approach of the bowel, addressing anticipated challenges when eventually translating molecular US imaging into the clinic, such as the need to image a large volume to obtain representative images of inflamed bowel segments, along with spatial orientation to reliably localize inflamed bowel segments within the large field of view of the bowel, as well as the need to reduce possible artifacts from intraluminal gas and motion. Following successful completion of our research aims, we anticipate rapid translation of this patient-friendly, non-invasive and quantitative imaging technique into the clinic to improve clinical management and outcome of patients with IBD.
Funding Period: 2012-08-05 - 2017-06-30
more information: NIH RePORT
- Molecular imaging of inflammation in inflammatory bowel disease with a clinically translatable dual-selectin-targeted US contrast agent: comparison with FDG PET/CT in a mouse modelHuaijun Wang
Department of Radiology, Molecular Imaging Program at Stanford, Stanford University School of Medicine, 300 Pasteur Dr, Room H1307 Stanford, CA 94305 5621, USA
Radiology 267:818-29. 2013....
- Acoustic and photoacoustic molecular imaging of cancerKatheryne E Wilson
Department of Radiology, Molecular Imaging Program at Stanford, School of Medicine, Stanford University, Stanford, California
J Nucl Med 54:1851-4. 2013..These innovations may further improve our ability to detect and characterize tumors. In this review, recent developments in acoustic and photoacoustic molecular imaging of cancer are discussed. ..
- Ultrasound and microbubble guided drug delivery: mechanistic understanding and clinical implicationsWang Tzu-Yin
Department of Radiology and Molecular Imaging Program at Stanford, School of Medicine, Stanford University, 300 Pasteur Drive, Room H1307, Stanford, CA 94305 5621, USA
Curr Pharm Biotechnol 14:743-52. 2013..In this article, current progress in the mechanistic understanding of ultrasound and microbubble mediated drug delivery and its implications for clinical translation is discussed. ..
- Mechanisms and Markers of Prostate Cancer MetastasesROBERT LOUIS VESSELLA; Fiscal Year: 2013..It also conducts pre-clinical xenograft studies and provides statistical support to the overall P01 program. Core B is the Administrative Core which provides overall administrative support to the investigators. ..
- SPORE in Soft Tissue SarcomaSamuel Singer; Fiscal Year: 2013..abstract_text> ..
- Sensitive and Specific Molecular Imaging of Pulmonary NodulesBastiaan Driehuys; Fiscal Year: 2013..abstract_text> ..
- Digitalis-Induced Signaling by Cardiac Na+/K+-ATPaseAmir Askari; Fiscal Year: 2013..abstract_text> ..
- Co-registered photoacoustic and ultrasound imaging for non-invasive ovarian canQuing Zhu; Fiscal Year: 2013..abstract_text> ..
- Elafin Therapy for Lung DiseasesMarlene Rabinovitch; Fiscal Year: 2013..The Administrative Core facilitates exchange of information and postdoctoral training in Lung Translational Medicine, and facilitates our strategy to move elafin into clinical trial in the next cycle. ..
- Reducing Cervical Cancer in AppalachiaElectra D Paskett; Fiscal Year: 2013..Future work of this Center will focus on moving this type of multi-level observational and interventional community-based research, into other areas where health disparities exist in relation to cancer withinour region. ..
- Molecular Ultrasound for Early Breast Cancer DetectionJUERGEN KARL WILLMANN; Fiscal Year: 2013..Based on successful study results, we anticipate rapid translation of this technique into the clinic to improve patient survival and patient care by diagnosing breast cancer at an earlier stage. ..
- DIETARY AND HORMONAL DETERMINANTS OF CANCER IN WOMENMeir Stampfer; Fiscal Year: 2013..abstract_text> ..